|  | value |
| --- | --- |
| Survival status at last contact | |
| Alive | 1489 (90.74%) |
| Dead | 152 (9.26%) |
| Event-free survival (Graft failure or death are the events) | |
| Event happened | 404 (24.62%) |
| No event | 1212 (73.86%) |
| Not Reported | 25 (1.52%) |
| Graft failure | |
| Yes | 288 (17.55%) |
| No | 1323 (80.62%) |
| Not evaluable (Neutrophil recovery not reported) | 30 (1.83%) |
| Death without graft failure | |
| No | 1525 (92.93%) |
| Yes | 111 (6.76%) |
| Not Reported | 5 (0.3%) |
| Neutrophil engraftment | |
| Yes | 1584 (96.53%) |
| Not Reported | 36 (2.19%) |
| No | 21 (1.28%) |
| Death without neutrophil engraftment | |
| No | 1630 (99.33%) |
| Not Reported | 8 (0.49%) |
| Yes | 3 (0.18%) |
| Platelet recovery | |
| Yes | 1468 (89.46%) |
| Not Reported | 104 (6.34%) |
| No | 69 (4.2%) |
| Death without platelet recovery | |
| No | 1586 (96.65%) |
| Not Reported | 27 (1.65%) |
| Yes | 28 (1.71%) |
| Acute graft versus host disease, grades II-IV | |
| No | 1280 (78%) |
| Yes | 300 (18.28%) |
| Not reported | 22 (1.34%) |
| Acute GVHD present, grade unknown | 39 (2.38%) |
| Death without acute graft versus host disease, grades II-IV | |
| No | 1573 (95.86%) |
| Yes | 59 (3.6%) |
| Not Reported | 9 (0.55%) |
| Chronic graft-vs-host disease | |
| No | 1245 (75.87%) |
| Yes | 366 (22.3%) |
| Not Reported | 30 (1.83%) |
| Death without chronic graft-vs-host disease | |
| No | 1555 (94.76%) |
| Yes | 75 (4.57%) |
| Not Reported | 11 (0.67%) |
| Post-transplant lymphoproliferative disorder (PTLD) | |
| No | 1618 (98.6%) |
| Not Reported | 9 (0.55%) |
| Yes | 14 (0.85%) |
| Secondary malignancy | |
| None | 1610 (98.11%) |
| Acute myelogenous leukemia | 6 (0.37%) |
| Not Reported | 9 (0.55%) |
| Medulloblastoma | 1 (0.06%) |
| Embryonal rhabdomyosarcoma | 1 (0.06%) |
| Myelodysplastic syndrome | 4 (0.24%) |
| Ependymoma grade 2 | 1 (0.06%) |
| Myofibroblastic tumor | 1 (0.06%) |
| Clonal cytogenetic abnormality | 1 (0.06%) |
| TP53 mutation | 1 (0.06%) |
| T-cell large granular lymphocyte leukemia | 1 (0.06%) |
| Acute lymphoblastic leukemia | 2 (0.12%) |
| Sarcoma | 2 (0.12%) |
| Kaposi sarcoma | 1 (0.06%) |